The VALOR-HCM trial showed the benefits of mavacamten as an alternative to surgical septal myectomy or alcohol ablation in patients with severely symptomatic obstructive hypertrophic cardiomyopathy. It was a pleasure to speak with Prof. Milind Desai (Cleveland Clinic, Cleveland, OH) about the VALOR-HCM trial including the efficacy and safety endpoints of it and what future studies of mavacamten are planned.
Questions:
- Could you tell us a little about the VALOR-HCM trial? (00:21)
- What questions remain unanswered about the health benefits of mavacamten, and what future studies are planned? (04:45)
Disclosures: Milind Desai is a consultant for Bristol Myers Squibb and Medtronic.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Filmed in coverage of the American College of Cardiology Annual Meeting 2022
